Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Therapy for Low, Intermediate, and High Risk Rhabdomyosarcoma
NCT01871766Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Dec 2013
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab, sorafenib, vincristine sulfate liposome injection, actinomycin D and cyclophosphamide in rhabdomyosarcoma (RMS) (4 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Event-Free Survival at 2 years. Started Dec 2013; status: active, not recruiting.
02
Drugs
bevacizumabsorafenibvincristine sulfate liposome injectionactinomycin Dcyclophosphamide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT01871766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871766.